18 Nov

XBI Rises in Contrast to a Flat Market

WRITTEN BY Peter Neil

XBI rises in a flat market

The market remained flat on November 17, 2015. The Dow Jones Industrial Average rose just 0.05%. In contrast, the S&P 500 fell by 0.15%.

The biotech (biotechnology) sector moved in the opposite direction of the market. The SPDR S&P Biotech ETF (XBI) rose 0.75% on November 17, and the iShares Nasdaq Biotechnology ETF (IBB) rose 1.3%. In contrast, the broader market representative, the SPDR S&P 500 ETF (SPY), fell by 0.05%.

XBI Rises in Contrast to a Flat Market

The market breadth for biotech stocks was positive. Out of XBI’s 101 holdings, 70 stocks ended in the positive, while 31 stocks ended in the red. XBI closed at $68.65 on November 17 and was trading below its 50- and 100-day moving averages.

The above graph reflects the performance of XBI in comparison to SPY. Since the beginning of November 2015, XBI has returned 3.3%, while SPY has returned -1.2% in the same period. So far, XBI has outperformed SPY.

PTC Therapeutics gains 7.3% on high trading volumes

PTC Therapeutics (PTCT) rose 7.3% and was the top performer within XBI. The stock rose on high trading volumes, with ~1.3 million shares being traded compared to its five-day average trading volume of ~768,000 shares per day.

PTCT closed at $33.09 and was trading above its 50-day moving average but below its 100-day moving average. The RSI (relative strength index) of the stock is at 56, indicating that it is neither overbought nor oversold.

PTCT has a book value of $7.34 per share. With its current price, the stock is trading at a price-to-book value (or PBV) of 4.51x. PTCT will be presenting at the Stifel 2015 Healthcare Conference held on November 18, 2015. PTCT has a weight of 0.90% in XBI’s portfolio.

Other stocks that performed well were bluebird bio (BLUE), Novavax (NVAX), and Incyte (INCY), which gave returns of 7.0%, 6.6%, and 5%, respectively.

Latest articles

US crude oil production has more than doubled since 2009 and grew by 1.1% over the last year. Currently, there are 133 operable refineries in the US.

The cannabis industry is fighting against the ongoing US-China trade war and recessionary worries, which have hurt valuations across the global market.

Higher revenues, increased ticket prices, and lower fuel costs are likely to drive American Airlines' Q3 earnings higher despite its Boeing MAX woes.

HEXO plans to report its Q4 earnings before the market opens on October 24. October has been tough for Hexo, with its stock falling 31.2% as of October 18.

Today, Advanced Micro Devices (AMD) rose 4% to over $32, making it one of the top Nasdaq gainers. Morgan Stanley raised its price target for AMD stock.

Early in 2019, President Donald Trump warned that China could overtake the US as a global power. He vowed that this would not happen under his leadership.